Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD.

JAMA. 1997 May 14;277(18):1445-51. Erratum in: JAMA 1997 Jul 9;278(2):118.

PMID:
9145716
3.

Prognostic markers in clinically localized prostate cancer.

Pettaway CA.

Tech Urol. 1998 Mar;4(1):35-42. Review.

PMID:
9568775
4.

The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.

Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL.

BJU Int. 2010 May;105(10):1417-22. doi: 10.1111/j.1464-410X.2010.09290.x. Epub 2010 Mar 15. Review.

5.

Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy.

Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, Partin A, Walsh PC.

J Urol. 1992 Jul;148(1):87-91. Review.

PMID:
1613888
6.

The clinical usefulness of prostate specific antigen: update 1994.

Partin AW, Oesterling JE.

J Urol. 1994 Nov;152(5 Pt 1):1358-68. Review.

PMID:
7523702
7.

[Innovative concepts in early cancer detection and staging of localized prostate cancer].

Rinnab L, K├╝fer R, Hautmann RE, Volkmer BG, Straub M, Blumstein NM, Gottfried HW.

Urologe A. 2005 Nov;44(11):1262, 1264-6, 1268-70, 1272-5. Review. German.

PMID:
16247635
8.

Clinical, pathological and molecular prognostic factors in prostate cancer decision-making process.

Pugliese D, Palermo G, Totaro A, Bassi PF, Pinto F.

Urologia. 2016 Jan-Mar;83(1):14-20. doi: 10.5301/uro.5000166. Epub 2016 Feb 24. Review.

PMID:
26917215
9.

A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.

Kent M, Vickers AJ.

J Urol. 2015 Jun;193(6):1938-42. doi: 10.1016/j.juro.2014.11.082. Epub 2014 Nov 15. Review.

10.

Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.

Kane CJ, Eggener SE, Shindel AW, Andriole GL.

Eur Urol Focus. 2017 Oct;3(4-5):487-497. doi: 10.1016/j.euf.2016.10.010. Epub 2017 Mar 11. Review.

PMID:
28753804
11.

Tissue biomarkers for prostate cancer radiation therapy.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.

Curr Mol Med. 2012 Jul 1;12(6):772-87. Review.

12.

Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.

Mohler JL, Williams BT, Thompson IM, Marshall ME.

J Cancer Res Clin Oncol. 1994;120 Suppl:S35-8. Review.

PMID:
8132702
13.

Critical review of prostate cancer predictive tools.

Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT.

Future Oncol. 2009 Dec;5(10):1555-84. doi: 10.2217/fon.09.121. Review.

14.

Problems and perspectives on the use of decision-analysis models for prostate cancer.

Simpson KN.

J Urol. 1994 Nov;152(5 Pt 2):1888-93. Review.

PMID:
7933245
15.

Localized prostate cancer.

Kapoor A, Hotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S138-S139. Review. No abstract available.

Supplemental Content

Support Center